Transforming growth factor-β family ligands can function as antagonists by competing for type II receptor binding

Journal of Biological Chemistry

Volumn 291, Issue 20, 2016, Pages 10792-10804

  Aykul, Senem ^a   Martinez Hackert, Erik ^a  

^a Michigan State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOPHAGES; EPITOPES; GLYCOPROTEINS; PHYSIOLOGICAL MODELS; PHYSIOLOGY; SIGNAL TRANSDUCTION; SIGNALING;

CELLULAR RESPONSE; DISEASE PHENOTYPES; HIGH AFFINITY LIGANDS; INTEGRAL FUNCTION; PHYSIOLOGICAL ACTIVITY; SIGNAL TRANSDUCTION SYSTEM; SIGNALING ACTIVITY; TRANSFORMING GROWTH FACTOR BETA;

LIGANDS;

ACTIVIN A; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 9; EPITOPE; OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR ACTRIIA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR ACTRIIB; TRANSFORMING GROWTH FACTOR BETA RECEPTOR BMPRII; UNCLASSIFIED DRUG; ACTIVIN; ACTIVIN RECEPTOR 2; BMP10 PROTEIN, HUMAN; BMP2 PROTEIN, HUMAN; BMP7 PROTEIN, HUMAN; BMPR2 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; FOLLISTATIN; GDF2 PROTEIN, HUMAN; GROWTH DIFFERENTIATION FACTOR; LIGAND; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BINDING AFFINITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; BINDING COMPETITION; DRUG EFFECT; HEP-G2 CELL LINE; METABOLISM; TUMOR CELL LINE;

ACTIVIN RECEPTORS, TYPE II; ACTIVINS; BINDING, COMPETITIVE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 7; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; BONE MORPHOGENETIC PROTEINS; CELL LINE, TUMOR; FOLLISTATIN; GROWTH DIFFERENTIATION FACTOR 2; GROWTH DIFFERENTIATION FACTORS; HEP G2 CELLS; HUMANS; LIGANDS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84969240504     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.713487     Document Type: Article

References (74)

1. Moustakas, A., and Heldin, C. H. (2009) The regulation of TGFβ signal transduction. Development 136, 3699-3714
2. Wrana, J. L. (2013) Signaling by the TGFβ superfamily. Cold Spring Harb. Perspect. Biol. 5, a011197
3. Massagué, J. (1998) TGF-β signal transduction. Annu. Rev. Biochem. 67, 753-791
4. Shi, Y., and Massagué, J. (2003) Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685-700
5. Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., and Massagué, J. (1994) Mechanism of activation of the TGF-β receptor. Nature 370, 341-347
6. Wrana, J. L., Attisano, L., Cárcamo, J., Zentella, A., Doody, J., Laiho, M., Wang, X. F., and Massagué, J. (1992) TGFβ signals through a heteromeric protein kinase receptor complex. Cell 71, 1003-1014
7. Weber, D., Kotzsch, A., Nickel, J., Harth, S., Seher, A., Mueller, U., Sebald, W., and Mueller, T. D. (2007) A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor. BMC Struct. Biol. 7, 6
8. Groppe, J., Hinck, C. S., Samavarchi-Tehrani, P., Zubieta, C., Schuermann, J. P., Taylor, A. B., Schwarz, P. M., Wrana, J. L., and Hinck, A. P. (2008) Cooperative assembly of TGF-β superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol. Cell 29, 157-168
9. Townson, S. A., Martinez-Hackert, E., Greppi, C., Lowden, P., Sako, D., Liu, J., Ucran, J. A., Liharska, K., Underwood, K. W., Seehra, J., Kumar, R., and Grinberg, A. V. (2012) Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex. J. Biol. Chem. 287, 27313-27325
10. Massagué, J. (2012) TGFβ signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616-630
11. Caja, L., Kahata, K., and Moustakas, A. (2012) Context-dependent action of transforming growth factor β family members on normal and cancer stem cells. Curr. Pharm. Des. 18, 4072-4086
12. Oshimori, N., and Fuchs, E. (2012) The harmonies played by TGF-β in stem cell biology. Cell Stem Cell 11, 751-764
13. Wu, M. Y., and Hill, C. S. (2009) Tgf-β superfamily signaling in embryonic development and homeostasis. Dev. Cell 16, 329-343
14. Heldin, C. H., Landström, M., and Moustakas, A. (2009) Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr. Opin. Cell Biol. 21, 166-176
15. Huminiecki, L., Goldovsky, L., Freilich, S., Moustakas, A., Ouzounis, C., and Heldin, C. H. (2009) Emergence, development and diversification of the TGF-β signalling pathway within the animal kingdom.BMCEvol. Biol. 9, 28
16. Sako, D., Grinberg, A. V., Liu, J., Davies, M. V., Castonguay, R., Maniatis, S., Andreucci, A. J., Pobre, E. G., Tomkinson, K. N., Monnell, T. E., Ucran, J. A., Martinez-Hackert, E., Pearsall, R. S., Underwood, K. W., Seehra, J., and Kumar, R. (2010) Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J. Biol. Chem. 285, 21037-21048
17. Cash, J. N., Rejon, C. A., McPherron, A. C., Bernard, D. J., and Thompson, T. B. (2009) The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding. EMBO J. 28, 2662-2676
18. Aykul, S., Ni, W., Mutatu, W., and Martinez-Hackert, E. (2015) Human cerberus prevents nodal-receptor binding, inhibits nodal signaling, and suppresses nodal-mediated phenotypes. PLoS ONE 10, e0114954
19. Sebald, W., Nickel, J., Zhang, J. L., and Mueller, T. D. (2004) Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction. Biol. Chem. 385, 697-710
20. Rosenzweig, B. L., Imamura, T., Okadome, T., Cox, G. N., Yamashita, H., ten Dijke, P., Heldin, C. H., and Miyazono, K. (1995) Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl. Acad. Sci. U.S.A. 92, 7632-7636
21. Attisano, L., Wrana, J. L., Montalvo, E., and Massagué, J. (1996) Activation of signalling by the activin receptor complex. Mol. Cell. Biol. 16, 1066-1073
22. Kirsch, T., Sebald, W., and Dreyer, M. K. (2000) Crystal structure of the BMP-2-BRIA ectodomain complex. Nat. Struct. Biol. 7, 492-496
23. David, L., Mallet, C., Mazerbourg, S., Feige, J. J., and Bailly, S. (2007) Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109, 1953-1961
24. Scharpfenecker, M., van Dinther, M., Liu, Z., van Bezooijen, R. L., Zhao, Q., Pukac, L., Löwik, C. W., and ten Dijke, P. (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 120, 964-972
25. Mitchell, D., Pobre, E. G., Mulivor, A. W., Grinberg, A. V., Castonguay, R., Monnell, T. E., Solban, N., Ucran, J. A., Pearsall, R. S., Underwood, K. W., Seehra, J., and Kumar, R. (2010) ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol. Cancer Ther. 9, 379-388
26. Greenwald, J., Groppe, J., Gray, P., Wiater, E., Kwiatkowski, W., Vale, W., and Choe, S. (2003) The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol. Cell 11, 605-617
27. Hinck, A. P. (2012) Structural studies of the TGF-βs and their receptors-insights into evolution of the TGF-β superfamily. FEBS Lett. 586, 1860-1870
28. Rejon, C. A., Hancock, M. A., Li, Y. N., Thompson, T. B., Hébert, T. E., and Bernard, D. J. (2013) activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells. Cell. Signal. 25, 2717-2726
29. Aykul, S., and Martinez-Hackert, E. (2016) New ligand binding function of human Cerberus and the role of proteolytic processing in regulating ligand-receptor interactions and antagonist activity. J. Mol. Biol. 428, 590-602
30. Piek, E., Afrakhte, M., Sampath, K., van Zoelen, E. J., Heldin, C. H., and ten Dijke, P. (1999) Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells. J. Cell. Physiol. 180, 141-149
31. Gamer, L. W., Nove, J., Levin, M., and Rosen, V. (2005) BMP-3 is a novel inhibitor of both activin and BMP-4 signaling in Xenopus embryos. Dev. Biol. 285, 156-168
32. Kokabu, S., Gamer, L., Cox, K., Lowery, J., Tsuji, K., Raz, R., Economides, A., Katagiri, T., and Rosen, V. (2012) BMP3 suppresses osteoblast differentiation of bone marrow stromal cells via interaction with Acvr2b. Mol. Endocrinol. 26, 87-94
33. Olsen, O. E., Wader, K. F., Hella, H., Mylin, A. K., Turesson, I., Nesthus, I., Waage, A., Sundan, A., and Holien, T. (2015) activin A inhibits BMPsignaling by binding ACVR2A and ACVR2B. Cell Commun. Signal. 13, 27
34. Klammert, U., Mueller, T. D., Hellmann, T. V., Wuerzler, K. K., Kotzsch, A., Schliermann, A., Schmitz, W., Kuebler, A. C., Sebald, W., and Nickel, J. (2015) GDF-5 can act as a context-dependent BMP-2 antagonist. BMC Biol. 13, 77
35. Wiater, E., and Vale, W. (2003) Inhibin is an antagonist of bone morphogenetic protein signaling. J. Biol. Chem. 278, 7934-7941
36. Martens, J. W., de Winter, J. P., Timmerman, M. A., McLuskey, A., van Schaik, R. H., Themmen, A. P., and de Jong, F. H. (1997) Inhibin interferes with activin signaling at the level of the activin receptor complex in Chinese hamster ovary cells. Endocrinology 138, 2928-2936
37. Lebrun, J. J., and Vale, W. W. (1997) activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation. Mol. Cell. Biol. 17, 1682-1691
38. Werner, S., and Grose, R. (2003) Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 83, 835-870
39. Chen, J. L., Walton, K. L., Winbanks, C. E., Murphy, K. T., Thomson, R. E., Makanji, Y., Qian, H., Lynch, G. S., Harrison, C. A., and Gregorevic, P. (2014) Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 28, 1711-1723
40. Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S., Lacey, D. L., Goldberg, A. L., and Han, H. Q. (2010) Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142, 531-543
41. Baker, J. M., and Boyce, F. M. (2014) High-throughput functional screening using a homemade dual-glow luciferase assay. J. Vis. Exp. 10.3791/50282
42. Harada, K., Shintani, Y., Sakamoto, Y., Wakatsuki, M., Shitsukawa, K., and Saito, S. (1996) Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J. Clin. Endocrinol. Metab. 81, 2125-2130
43. Suragani, R. N., Cadena, S. M., Cawley, S. M., Sako, D., Mitchell, D., Li, R., Davies, M. V., Alexander, M. J., Devine, M., Loveday, K. S., Underwood, K. W., Grinberg, A. V., Quisel, J. D., Chopra, R., Pearsall, R. S., et al. (2014) Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat. Med. 20, 408-414
44. Kropf, J., Schurek, J. O., Wollner, A., and Gressner, A. M. (1997) Immunological measurement of transforming growth factor-β1 (TGF-β1) in blood; assay development and comparison. Clin. Chem. 43, 1965-1974
45. De Crescenzo, G., Pham, P. L., Durocher, Y., and O'Connor-McCourt, M. D. (2003) Transforming growth factor-β (TGF-β) binding to the extracellular domain of the type II TGF-β receptor: receptor capture on a biosensor surface using a new coiled-coil capture system demonstrates that avidity contributes significantly to high affinity binding. J. Mol. Biol. 328, 1173-1183
46. Baardsnes, J., Hinck, C. S., Hinck, A. P., and O'Connor-McCourt, M. D. (2009) TβR-II discriminates the high-and low-affinity TGF-β isoforms via two hydrogen-bonded ion pairs. Biochemistry 48, 2146-2155
47. Schmierer, B., and Hill, C. S. (2007) TGFβ-SMAD signal transduction: molecular specificity and functional flexibility. Nat. Rev. Mol. Cell Biol. 8, 970-982
48. Korchynskyi, O., and ten Dijke, P. (2002) Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J. Biol. Chem. 277, 4883-4891
49. Zawel, L., Dai, J. L., Buckhaults, P., Zhou, S., Kinzler, K. W., Vogelstein, B., and Kern, S. E. (1998) Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1, 611-617
50. Liu, I. M., Schilling, S. H., Knouse, K. A., Choy, L., Derynck, R., and Wang, X. F. (2009) TGFβ-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFβ switch. EMBO J. 28, 88-98
51. Daly, A. C., Randall, R. A., and Hill, C. S. (2008) Transforming growth factor β-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol. Cell. Biol. 28, 6889-6902
52. Wrighton, K. H., Lin, X., Yu, P. B., and Feng, X. H. (2009) Transforming growth factor β can stimulate smad1 phosphorylation independently of bone morphogenic protein receptors. J. Biol. Chem. 284, 9755-9763
53. Kirkbride, K. C., Townsend, T. A., Bruinsma, M. W., Barnett, J. V., and Blobe, G. C. (2008) Bone morphogenetic proteins signal through the transforming growth factor-β type III receptor. J. Biol. Chem. 283, 7628-7637
54. López-Casillas, F., Wrana, J. L., and Massagué, J. (1993) β-Glycan presents ligand to the TGFβ signaling receptor. Cell 73, 1435-1444
55. Pearsall, R. S., Canalis, E., Cornwall-Brady, M., Underwood, K. W., Haigis, B., Ucran, J., Kumar, R., Pobre, E., Grinberg, A., Werner, E. D., Glatt, V., Stadmeyer, L., Smith, D., Seehra, J., and Bouxsein, M. L. (2008) A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc. Natl. Acad. Sci. U.S.A. 105, 7082-7087
56. Laping, N. J., Grygielko, E., Mathur, A., Butter, S., Bomberger, J., Tweed, C., Martin, W., Fornwald, J., Lehr, R., Harling, J., Gaster, L., Callahan, J. F., and Olson, B. A. (2002) Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity: SB-431542. Mol. Pharmacol. 62, 58-64
57. Inman, G. J., Nicolás, F. J., Callahan, J. F., Harling, J. D., Gaster, L. M., Reith, A. D., Laping, N. J., and Hill, C. S. (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 62, 65-74
58. Amthor, H., Christ, B., Rashid-Doubell, F., Kemp, C. F., Lang, E., and Patel, K. (2002) Follistatin regulates bone morphogenetic protein-7 (BMP-7) activity to stimulate embryonic muscle growth. Dev. Biol. 243, 115-127
59. Iemura, S., Yamamoto, T. S., Takagi, C., Uchiyama, H., Natsume, T., Shimasaki, S., Sugino, H., and Ueno, N. (1998) Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc. Natl. Acad. Sci. U.S.A. 95, 9337-9342
60. Massagué, J. (2000) How cells read TGF-β signals. Nat. Rev. Mol. Cell Biol. 1, 169-178
61. de Kretser, D. M., O'Hehir, R. E., Hardy, C. L., and Hedger, M. P. (2012) The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol. Cell. Endocrinol. 359, 101-106
62. Phillips, D. J., de Kretser, D. M., and Hedger, M. P. (2009) activin and related proteins in inflammation: not just interested bystanders. Cytokine Growth Factor Rev. 20, 153-164
63. Moura, J., da Silva, L., Cruz, M. T., and Carvalho, E. (2013) Molecular and cellular mechanisms of bone morphogenetic proteins and activins in the skin: potential benefits for wound healing. Arch. Dermatol. Res. 305, 557-569
64. Werner, S., and Alzheimer, C. (2006) Roles of activin in tissue repair, fibrosis, and inflammatory disease. Cytokine Growth Factor Rev. 17, 157-171
65. Hully, J. R., Chang, L., Schwall, R. H., Widmer, H. R., Terrell, T. G., and Gillett, N. A. (1994) Induction of apoptosis in the murine liver with recombinant human activin A. Hepatology 20, 854-862
66. Chen, Y. G., Lui, H. M., Lin, S. L., Lee, J. M., and Ying, S. Y. (2002) Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp. Biol. Med. 227, 75-87
67. Thompson, T. B., Lerch, T. F., Cook, R. W., Woodruff, T. K., and Jardetzky, T. S. (2005) The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev. Cell 9, 535-543
68. Rebbapragada, A., Benchabane, H., Wrana, J. L., Celeste, A. J., and Attisano, L. (2003) Myostatin signals through a transforming growth factor β-like signaling pathway to block adipogenesis. Mol. Cell. Biol. 23, 7230-7242
69. Lowery, J. W., Intini, G., Gamer, L., Lotinun, S., Salazar, V. S., Ote, S., Cox, K., Baron, R., and Rosen, V. (2015) Loss of BMPR2 leads to high bone mass due to increased osteoblast activity. J. Cell Sci. 128, 1308-1315
70. Hatsell, S. J., Idone, V., Wolken, D. M., Huang, L., Kim, H. J., Wang, L., Wen, X., Nannuru, K. C., Jimenez, J., Xie, L., Das, N., Makhoul, G., Chernomorsky, R., D'Ambrosio, D., Corpina, R. A., et al. (2015) ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci. Transl. Med. 7, 303ra137
71. Saunier, E. F., and Akhurst, R. J. (2006) TGF β inhibition for cancer therapy. Curr. Cancer Drug Targets 6, 565-578
72. Ruckle, J., Jacobs, M., Kramer, W., Pearsall, A. E., Kumar, R., Underwood, K. W., Seehra, J., Yang, Y., Condon, C. H., and Sherman, M. L. (2009) Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J. Bone Miner. Res. 24, 744-752
73. Antsiferova, M., and Werner, S. (2012) The bright and the dark sides of activin in wound healing and cancer. J. Cell Sci. 125, 3929-3937
74. Thompson, T. B., Woodruff, T. K., and Jardetzky, T. S. (2003) Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-β ligand:receptor interactions. EMBO J. 22, 1555-1566